Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
Matti S. Aapro
Consultant or Advisory Role - Helsinn Therapeutics
Honoraria - Helsinn Therapeutics
Research Funding - Helsinn Therapeutics
Other Remuneration - Helsinn Therapeutics
Giorgia Rossi
Employment or Leadership Position - Helsinn Therapeutics
Giada Rizzi
Employment or Leadership Position - Helsinn Therapeutics
Marco Palmas
Employment or Leadership Position - Helsinn Therapeutics
Steven Grunberg
Consultant or Advisory Role - A.P. Pharma; Helsinn Therapeutics; Merck Sharp & Dohme; RedHill Biopharma; Tesaro
Stock Ownership - Merck
Honoraria - Eisai; Merck